Results 151 to 160 of about 80,955 (206)

Dual inhibition of ATR and PARP reverses acquired PARP inhibitor resistance in triple negative breast cancer. [PDF]

Discov Oncol
Guney Eskiler G, Haciefendi A, Ozdemir K, Bilir C.   +3 more
europepmc   +1 more source

PARP inhibitor and PRMT5 inhibitor synergy is independent of BRCA1/2 and MTAP status in breast cancer cells. [PDF]

Sci Rep
Suresh S, McPherson L, Ford JM.
europepmc   +1 more source

Differential PARP inhibitor responses in BRCA1-deficient and resistant cells in competitive co-culture. [PDF]

PLoS One
Soetomo SA, Sharp MF, Crismani W.
europepmc   +1 more source

Metabolic subtyping reveals PDIK1L as a dual-functional regulator of progression and PARP inhibitor sensitivity in prostate cancer. [PDF]

Front Cell Dev Biol
Wang Z, Ge Q, Aihetaimujiang A, Zhang J, Lu J, Yang J, Chen Y, Qin B, Zhang H, Xu WH, Ye D.   +10 more
europepmc   +1 more source

Comprehensive genomic profiling for homologous recombination deficiency guides PARP inhibitor therapy recommendations in ovarian cancer. [PDF]

Pathol Oncol Res
Inci A, Witzel I, Moch H, Rahmani-Khajouei S, Zoche M, Samartzis EP.   +5 more
europepmc   +1 more source

Genetic evidence for PARP1 trapping as a driver of PARP inhibitor efficacy in BRCA mutant cancer cells. [PDF]

Nucleic Acids Res
Ribeiro J, Hansen K, van Beek L, Stubbs C, Frigola J, Talbot S, Bentouati S, Hall J, Wijnhoven PWG, Armenia J, Schimpl M, Forment JV, Albertella MR, O'Connor MJ, Illuzzi G.   +14 more
europepmc   +1 more source

The Real-World Impact of PARP Inhibitor Maintenance Therapy in High Grade Serous Tubo-Ovarian and Peritoneal Cancers. [PDF]

Cancers (Basel)
Al-Ani M, Baraka B, Mathiyalagan N, Sarwar MA, Segaran A, Abuzahra W, Radford A, Buxton K, Seneviratne L, Sundar S, Anand A, Nunns D, Williamson K, Wormald B, Gajjar K, Madhusudan S.   +15 more
europepmc   +1 more source

PARP Inhibitor Maintenance After First-Line Chemotherapy in Advanced-Stage Epithelial Ovarian Cancer: A Systematic Review and Meta-Analysis.

JAMA Netw Open
Petousis S, Kahramanoglu I, Appenzeller-Herzog C, Angeles MA, Margioula-Siarkou C, Kacperczyk-Bartnik J, Bilir E, Chatzakis C, Caruso G, Bizzarri N, Dinas K, Bowtell DDL, Garsed DW, Ray-Coquard I, Ledermann JA, Friedlander M, Sotiriadis A, Heinzelmann-Schwarz V, Zwimpfer TA.   +18 more
europepmc   +1 more source

PARP inhibitor combination therapy

Critical Reviews in Oncology/Hematology, 2016
In 2014, olaparib (Lynparza) became the first PARP (Poly(ADP-ribose) polymerase) inhibitor to be approved for the treatment of cancer. When used as single agents, PARP inhibitors can selectively target tumour cells with BRCA1 or BRCA2 tumour suppressor ...
Christopher J Lord, Alan Ashworth
exaly   +5 more sources

Some of the next articles are maybe not open access.

Related searches:

PARP Inhibitors

Current Breast Cancer Reports, 2011
Poly (ADP-ribose) polymerase (PARP) is a novel therapeutic target in cancer. Preclinical studies demonstrate that PARP inhibitors selectively kill BRCA-deficient cells and potentiate the effects of DNA-damaging agents. There are several PARP inhibitors in clinical development, including olaparib, iniparib, veliparib, PF-01367338, and MK-4827.
Hongyan Liang, Antoinette R. Tan
openaire   +2 more sources